Renovaro Biosciences is a biotechnology company engaged in developing allogeneic cell and gene therapies to promote stronger immune system responses for long-term or life-long cancer remission in cancers, and potentially to treat or cure diseases such as Human Immunodeficiency Virus (HIV) and Hepatitis B virus (HBV) infection. Co.'s product candidates include: RENB-DC-11 for the indication of dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX for the indication of dendritic cell therapeutic vaccine for other solid tumors; RENB-HV-12 for the indication of HIV therapeutic vaccine; and RENB-HV-01 for the indication of HIV autologous transplant and HBV gene therapy. The RENB stock yearly return is shown above.
The yearly return on the RENB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RENB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|